PEX010

PEX010 is a proprietary, botanical psilocybin drug candidate developed by Filament Health. It is formulated as an oral capsule containing 25 mg of naturally derived psilocybin. PEX010 acts as a serotonergic psychedelic, primarily targeting the serotonin 2A receptor (5-HT2A), and is being investigated for its potential to reduce substance use and improve mental health outcomes in various psychiatric conditions. Clinical studies have demonstrated that a single dose of PEX010 can significantly reduce heavy drinking days in patients with alcohol use disorder, with additional trials underway for opioid use disorder, methamphetamine use disorder, cancer-related anxiety, demoralization syndrome in palliative care settings, major depressive disorder, and end-of-life distress. The drug has shown a favorable safety profile and sustained efficacy across multiple indications[1][2][3][4][5][6][7].

Other names

psilocybin